SHERIDAN, WYOMING – May 27, 2025 – In a pivotal move to diversify its production capabilities, Plural Industria Grafica LTDA, one of South America's leading offset printing firms, has integrated sheetfed offset technology from Heidelberger Druckmaschinen AG (HEIDELBERG) into its operations for the first time. This landmark decision underscores Plural's commitment to capturing new market segments and enhancing cost-efficiency for shorter print runs.

Expanding Beyond Traditional Web Offset

SHERIDAN, WYOMING – May 27, 2025 – Heidelberger Druckmaschinen AG (HEIDELBERG) has successfully navigated a challenging economic landscape, achieving its fiscal year 2024/25 targets while laying the groundwork for further growth in 2025/26. The company maintained a stable adjusted EBITDA margin of 7.1 percent and generated a clearly positive free cash flow of around €50 million, despite rising wage costs, a slightly lower sales volume, and expenses related to the drupa trade fair.

SHERIDAN, WYOMING – May 27, 2025 – Seaway Printing has taken a bold step toward fully autonomous production, becoming the first U.S. customer to implement HEIDELBERG’s Plate to Unit system, and integrating the world’s first Inline Splicer with the CutStar generation 4 sheeter. The move is part of a sweeping automation strategy aimed at significantly improving productivity and operational efficiency across Seaway’s expanded Wisconsin facility.

SHERIDAN, WYOMING – May 27, 2025 – Roche has received a significant endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which issued a positive opinion for Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant. This recommendation positions Roche to offer a first-line treatment solution for adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer—an area with limited current treatment options.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced a new strategic collaboration with Broad Clinical Labs, aiming to accelerate the adoption of its next-generation Sequencing by Expansion (SBX) technology, with an initial focus on trio-based whole genome sequencing for critically ill newborns and their biological parents. The partnership signifies a pivotal move in expanding genomics-enabled healthcare and precision medicine at scale.

SHERIDAN, WYOMING – May 27, 2025 – Roche has unveiled compelling two-year follow-up data from its pivotal phase III STARGLO trial, reinforcing the long-term clinical value of Columvi® (glofitamab) in combination with chemotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). The results underscore the strategic impact of Roche’s bispecific antibody pipeline in addressing aggressive hematologic malignancies with limited treatment options.

SHERIDAN, WYOMING – May 27, 2025 – Roche has received FDA approval for Susvimo® (ranibizumab injection) 100 mg/mL as a new treatment for diabetic retinopathy (DR), marking a pivotal advancement in the battle against this vision-threatening condition that affects nearly 10 million Americans.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced an encouraging update on its supplemental Biologics License Application (sBLA) for Columvi® (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx), following discussion by the FDA’s Oncologic Drugs Advisory Committee (ODAC). The combination therapy demonstrated a significant 41% reduction in the risk of death in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) who are not candidates for autologous stem cell transplant.

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced FDA approval of its VENTANA® MET (SP44) RxDx Assay, marking a major milestone in companion diagnostics for non-small cell lung cancer (NSCLC). This approval paves the way for a more precise identification of patients eligible for AbbVie’s Emrelis™ (telisotuzumab vedotin-tllv), a targeted therapy for non-squamous NSCLC with MET protein overexpression.

Enhancing Treatment Precision in Lung Cancer Care

SHERIDAN, WYOMING – May 27, 2025 – Roche has announced compelling final results from the decade-long APHINITY Phase III clinical trial, demonstrating a significant 17% reduction in the risk of death for patients with HER2-positive early-stage breast cancer who received a Perjeta® (pertuzumab)-based adjuvant therapy. These findings reinforce the strategic role of the Perjeta-based regimen in long-term disease management and will be presented as a late-breaking abstract at the 2025 ESMO Breast Cancer Congress.